Rel-Zotatifin
Rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex[1].
Product Specifications
CAS Number
2098191-54-7
Product Name Alternative
Rel-eFT226
UNSPSC
12352005
Target
Apoptosis; Eukaryotic Initiation Factor (eIF) ; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/rel-zotatifin.html
Purity
97.32
Solubility
DMSO : 12.5 mg/mL (ultrasonic)
Smiles
N#CC1=CC=C([C@@]2(O3)[C@@](C4=C3C=C(OC)N=C4OC)(O)[C@H](O)[C@H](CN(C)C)[C@H]2C5=CC=CC=C5)C=C1
Molecular Formula
C28H29N3O5
Molecular Weight
487.56
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EIF4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 14 (KRT14) (Squamous Cell Marker) (KRT14/2375), CF488A conjugate, 0.1mg/mL
SHBG (Sex Hormone Binding Globulin) (SHBG/245), CF568 conjugate, 0.1mg/mL
